Company: HURA
Filing Date: 2025-11-18
Form Type: 8-K
Source: 0001193125-25-286419
Chunk: 0

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-11-18
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

Updated Pro Forma Financial Statements

As previously disclosed, on June 30, 2025, TuHURA Biosciences, Inc., a Nevada corporation (“ TuHURA”), completed its previously announced acquisition contemplated by the Agreement and Plan of Merger, dated December 11, 2024, as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the “ Merger Agreement”), by and among TuHURA, Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA (“ Merger Sub I”), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA (“ Merger Sub II”), Kineta, Inc., a Delaware corporation (“ Kineta”), and Craig Philips, solely in his capacity as the representative, agent and attorney-in-factof the stockholders of Kineta. Pursuant to the terms of the Merger Agreement, among other things, (a) Merger Sub I merged with and into Kineta (the “ First Merger”), with Kineta being the surviving corporation of the First Merger, also known as the “ Surviving Entity” and (b) immediately following the First Merger, the Surviving Entity merged with and into Merger Sub II (the “ Second Merger”, and together with the First Merger, the “ Mergers”), with Merger Sub II being the surviving company of the Second Merger.

TuHURA is providing as Exhibit 99.1 to this Current Report on Form8-K(the “ Report”) its unaudited pro forma condensed combined statement of operations for the nine months ended September 30, 2025, and the year ended December 31, 2024 on a pro forma basis as if the Mergers and TuHURA’s previously announced reverse merger with Kintara Therapeutics, Inc. that closed on October 18, 2024 had been consummated on January 1, 2024.